



ASX Announcement

Race secures A\$3m strategic investment from prominent biotechnology investors to drive bisantrene development

- Strategic placement at A\$0.60 per share to raise A\$3m
- Placement to three sophisticated biotechnology investors
- Fully funds the Phase II AML bisantrene combination trial planned to start late 2020

13 July 2020 – Race Oncology Limited (“Race” or “the Company”) (ASX: RAC) is pleased to advise that it has received firm commitments for A\$3.0 million (before costs) in new equity funding via a strategic placement (Placement) of five million ordinary shares, at an issue price \$0.60 per share. The issue price represents a 1.96% discount to the 15- trading day VWAP, in the context of a 138% rise in the Company’s share price over the past 30 days. No options are to be issued in conjunction with this placement.

The Placement has been made to three prominent biotechnology investors, Kidder Williams’ David Williams, EFM Asset Management’s Jeff Emmanuel and a follow-on investment by biotechnology institutional investor, Merchant Opportunities Fund (“Merchant”).

About the strategic investors

David Williams, Managing Director of specialist corporate advisory firm, Kidder Williams has over 30 years’ experience providing mergers and acquisitions, capital raising and strategic advice. David is the Chairman of the ASX-listed companies Medical Developments International Limited (ASX: MVP), Rate My Agent (ASX: RMY) and PolyNovo Limited (ASX: PNV).

Jeff Emmanuel is Director of growth oriented global equities asset manager, EFM Asset Management (Hong Kong). Jeff’s investment philosophy is to identify growth opportunities that present themselves as emerging winners, backing the individuals behind what he identifies as a successful business. He has made prior ASX investments in PolyNovo (ASX: PNV), BARD1 (ASX: BD1) and Sienna Cancer Diagnostics (ASX: SDX).

The Merchant Opportunities Fund is a boutique fund with a number of long term strategic investments in the Australian biotechnology industry. Merchant made an initial A\$1.8m investment in Race during March 2020, for six million ordinary shares at an issue price of \$0.30 (ASX announcement: March 6, 2020).

Use of funds and timetable

The current placement provides Race with sufficient resources to fund the bisantrene Phase II combination AML trial, planned to begin in late 2020. Several other important initiatives associated with the 5-path clinical development plan are currently underway and the Company looks forward to updating shareholders in the near-term.

Shares under the placement are expected to be allotted and issued by Wednesday, 15 July 2020, and will rank equally with the existing ordinary shares on issue. The new shares will be issued pursuant to the Company’s existing placement capacity under ASX listing rule 7.1.

Management commentary:

Race's Executive Chairman, Dr John Cullity commented, "We are encouraged by the unsolicited approach and interest of these three sophisticated investors in Race following the release of new bisantrene data in June. This placement has been conducted to strengthen Race's balance sheet, providing the funding needed to progress our clinical plans, while introducing further experienced, specialist investors to our register."

Race's Chief Scientific Officer Dr Daniel Tillett said, "To have attracted this level of support from such prominent investors with a proven track record of identifying promising early stage life sciences companies is a significant validation of Race's clinical potential. We thank them for their support and are now fully funded to progress the Phase II AML combination clinical trial of bisantrene and other activities. We look forward to reporting progress on our clinical trials and related activities in the months ahead."

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Daniel Tillett, Chief Scientific Officer & Director

daniel.tillett@raceoncology.com

Media contact:

Jane Lowe, IR Department

+ 61 411 117 774

jane.lowe@irdepartment.com.au